ArticleCell transplantation
Incidence and clinical relevance of donor-derived recipient-specific anti-HLA antibodies in haploidentical hematopoietic stem cell transplantation: a retrospective study.
Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donor-derived recipient-specific anti-HLA antibodies (RSAs) are rarely investigated in allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this retrospective study, 185 haploidentical donor-recipient pairs were consecutively analyzed. Anti-HLA antibodies were detected in eight donors (4.3%) and 31 recipients (16.8%), with only one donor (0.5%) harboring RSAs. Donors were predominantly young, male, and transfusion-naïve, which likely contributed to the low antibody prevalence. No association was observed between donor antibody positivity and graft rejection or severe acute graft-versus-host disease (GVHD). However, recipients of antibody-positive grafts showed higher rates of Epstein-Barr virus (EBV) reactivation and transfusion refractoriness. Our findings suggest that donor-derived HLA antibodies, particularly RSAs, are infrequent and clinically limited under current haploidentical donor selection and immunosuppressive strategies, but may subtly influence post-transplant immune recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.